with B cell adrenoceptors have been reported. This study evaluated the possible role of such interactions in the stimulation of insulin release. Mouse islets were incubated in the presence of 10 mmol/!L glucose alone or with tolbutamide (10gmol/1) or glibenclamide (0.02gmol/1). At 0.01-10 gmol/1, blockers of c~2-adrenoceptors (yohimbine, idazoxan) or cq-adrenoceptors (prazosin) had practically no effect on glucose-induced insulin release and did not affect its potentiation by sulphonylureas, except for a slight increase by 10 gmol/1 prazosin and idazoxan. Nonspecific a-blockers (phentolamine, dihydroergotamine) increased control release at 10 gmol/1, but only the latter amplified the response to tolbutamide. Blockers of [3-adrenoceptors were tested at 0.1-100gmol/l: propranolol ([3~, ~2), metoprolol (130 and compound ICI 118-551 (~2). They increased glucose-induced insulin release at 100 ~tmol/1 but variably altered the effect of sulphonylureas. Blockers of adrenoceptors have, thus, no effect on insulin release in vitro at therapeutic concentrations. At high concentrations, they non-specifically affect the action of sulphonylureas. We conclude that an interaction with B cell adrenoceptors is not involved in the insulinotropic action of sulphonylureas.
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Tolbutamide and glibenclamide displace c~-and [3-adrenergic radioligands in islet cells [1] , and blockers of o~-and [3-adrenoceptors have been reported to affect sulphonylurea-induced insulin release in man [2] or in dogs [3] [4] [5] . These observations raise the possibility that sulphonylureas may influence insulin release by interacting with adrenoceptors in B cells. To test this hypothesis, isolated mouse islets were stimulated here by tolbutamide and glibenclamide in the presence of specific or non-specific blockers of c~-and [3-adrenoceptors. The blockers were used at four concentrations, of which the lower two approximately encompass the therapeutic range, and the higher two are lethal [6] . diluted for measurement of immunoreactive insulin with rat insulin as standard [7] .
The medium used had the following ionic composition (retool/I): NaC1 120, KC14.8, CaC12 2.5, MgC12 1.2, NaHCO3 24. It was gassed with O2/CO2 (94: 6) to maintain a pH of 7.4, and was supplemented with bovine serum albumin (1 mg/ml).
The sources of test substances were as follows: tolbutamide and glibenclamide (Hoechst A.G., Frankfurt, FRG); dihydroergotamine (Sandoz Pharmaceuticals, Basel, Switzerland); phentolamine mesilate (Ciba-Geigy, Basel, Switzerland); prazosin hydrochloride (Pfizer, Brussels, Belgium); yohimbine hydrochloride (Aldrich Europe, Beerse, Belgium); idazoxan (Reckitt & Colman, Kingston, UK); dl-propranotol and compound IC1118-551 (ICI Ltd, Macclesfield, UK); metoprolol (Astra Nobel Pharma, Brussels, Belgium). All other reagents were from Merck AG (Darmstadt, FAG).
Materials and methods
All experiments were performed with islets isolated after collagenase digestion of the pancreas of fed female NMRI mice (25-30 g). Immediately after isolation, the islets were preincubated for 45 min at 37~ in a medium containing 10 mmol/1 glucose. Batches of three islets were then incubated for 60 min in 1 ml of medium containing 10 mmol/l glucose alone or with tolbutamide (10 gmol/1) or glibenclamide (0.02 gmol/1), and appropriate concentrations of test compounds. At the end of the incubation a portion of the medium was
Statistical analysis
Results are presented as means _+ SEM for the indicated number of batches of islets, obtained from four different islet preparations. All data were submitted to a two-way analysis of variance to assess the interaction between tolbutamide or glibenclamide and each test substance. The statistical significance of the effects of each test substance, with or without sulphonylurea, was then assessed by a test of Dunnett. 
Results
Insulin release by control islets amounted to 1.49 + 0.07 ng-islet ~. 60 rain-1 (H = 157) in the presence of 10mmol/1 glucose alone, to 6.53+0.25 ng.islet t. 60 min-~ (n = 154) when the medium was supplemented with 10 gmol/1 tolbutamide, and to 8.43 _+ 0.37 ng-islet = ~. 60min ~ (n=101) when the medium contained 0.02 ~tmol/1 glibenclamide.
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Insulin release induced by glucose alone was slightly increased by high concentrations of non-specific blockers of ~-adrenoceptors: 1-10 ~tmol/1 dihydroergotamine and 10 gmol/1 phentolamine (Fig. 1) . Both blockers had essentially similar effects when release was potentiated by tolbutamide or glibenclamide. Only 10 gmol/1 dihydroergotamine significantly enhanced the effect of tolbutamide (Fig. 1 a) .
Prazosin, a specific blocker of o~-adrenoceptors, was without effect on glucose-induced insulin release, but slightly increased the potentiating action of tolbutamide and glibenclamide at the high concentration of 10 gmol/1 ( Fig.2A and B) . Yohimbine, a specific blocker of (z2-adrenoceptors, had no influence on the insulin response to glucose alone nor on its potentiation by sulphonylureas ( Fig. 2C and D) . Idazoxan, another specific blocker of c~2-adrenoceptors, slightly increased glucose-induced insulin release and its potentiation by tolbutamide or glibenclamide, at least at the concentration of 10 pmol/1 ( Fig. 2 E and F) .
Glucose-induced insulin-release was increased fivefold by 100 gmol/1 propranolol, a non-specific blocker of 6-adrenoceptors. The potentiating effect of tolbutamide was also amplified by 10-100 ~tmol/1 propranolol and that of glibenclamide by 100 gmol/1 propranolol ( Fig. 3 A and  B) . Metoprolol, a specific blocker of 131-adrenoceptors, increased both glucose-induced insulin release and its potentiation by the two sulphonylureas only when used at the high concentration of 100 gmol/1 (Fig.3 C and D) . Compound ICI 118-551, a specific blocker of 132-adrenoceptors, had complex effects on insulin release. At the concentrations of 10 and 100 gmol/1, it enhanced the response to glucose. It also amplified the potentiating action of tolbutamide and glibenclamide at 10 gmol/1. However, this positive effect was not observed at 100 gmol/1, a con-
,~12 (~) centration that even inhibited the response to glibenclamide ( Fig. 3 E and F) .
Discussion
Both functional and binding studies have established that B cells are equipped with ~x2-adrenoceptors [8, 9] . [3-adrenoceptors have been identified on islet cells [10] , but their presence on B cells has been questioned [11] . In our freshly isolated islets, [3-agonists have no effect on glucose-induced insulin release, whereas as little as 1 nmol/1 adrenaline inhibits it by about one third (unpublished data). Moreover, the 85% inhibition produced by 100 nmol/1 adrenaline is completely prevented by i gmol/1 yohimbine [12] . This sensitivity is similar to that of cultured purified B cells [11] . It has long been known that high concentrations of phentolamine ( = 35 gmol/1) [13] and propranolol ( ~ 200 gmol/1) [14] increase insulin release in vitro. This is confirmed in the present study which further shows that other, though not all, ~x-and [3-blockers increased release at concentrations of 10-100 gmol/1. As these effects are unlikely to be specific, the underlying mechanisms were not investigated. A recent study has clearly shown that the stimulation of insulin release by 31 gmol/1 phentolamine is not due to blockade of o~-adrenoceptors [15] .
Binding studies have suggested that tolbutamide has a greater affinity for 13-adrenoceptors and glibenclamide for (x-adrenoceptors [1] . Our data did not reveal any preferential interaction of blockers of one type of adrenoceptors with one of the two sulphonylureas. Phentolamine and dihydroergotamine have been reported as amplifying tolbutamide-induced insulin release in vivo [3, 5] . Although we observed a similar effect in vitro with dihydroergotamine, this interaction cannot be taken as evidence of a role for c~-adrenoceptors in the response to sulphonylureas. Thus, it was not observed with all blockers and did not show specificity for 0~1-or c~2-adrenoceptors. Propranolol has been reported as decreasing tolbutamide-induced insulin release in vivo [2, 4] . No such effect was found in vitro. On the contrary, high concentrations of propranolol augmented the insulin response to tolbutamide and glibenclamide. The significance of this interaction is unclear since it was also observed with specific blockers of 131-and 132-adrenoceptors.
In conclusion, interactions between tolbutamide or glibenclamide and blockers of adrenoceptors only occur at very high concentrations of the latter and appear to be non-specific. As these concentrations are never reached in vivo [6] , no similar drug interactions at the B cell level should be anticipated in treated patients. Our results do not support the suggestion [1] that B cell adrenoceptors play a role in the stimulation of insulin release by sulphonylureas. On the other hand, they indirectly add to the evidence that K + channels of the B cell membrane are the sole target for these drugs [16] [17] [18] [19] .
